Compare Cognizant Technology Solutions Corp (CTSH) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Heron Therapeutics Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.25 (market cap $27.03B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Cognizant Technology Solutions Corp is far larger — about 397.4× Heron Therapeutics Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Heron Therapeutics Inc for 35 Days on average.
| CTSH | HRTX | |
|---|---|---|
Market Cap | $27.03B | $68.01M |
Volume | 9,883,888 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $86.70 | $1.49 |
52-Week Low | $38.73 | $0.27 |
Typical Hold Time | 57 Days | 35 Days |
Enterprise Value | $28.08B | $174.75M |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.20, up 3.73% today, with a bullish technical signal from moving averages and support at $56. The stock shows solid fundamentals with a P/E of 12.88, net income margin of 10.26%, and consistent earnings beats in recent quarters. Recent news highlights AI-driven initiatives and strong employer recognition, supporting positive sentiment.
CTSH presents a favorable risk-reward profile with a consensus price target of $64.25 offering ~8.5% upside. Key opportunities include AI integration and stable cash flow, while risks involve IT spending pressures and competitive threats. Analyst consensus is balanced between Buy and Hold ratings, reflecting cautious optimism amid industry headwinds.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
